Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Fezolinetant in Healthy Japanese Subjects
NCT03436849Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fezolinetant in vasomotor symptoms and menopause (9 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of adverse events at Day 24, Body temperature, Blood pressure, Pulse rate at Day 24 and 5 more. Started Feb 2018; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptomsmenopause
Beyond the preview
Go deeper on NCT03436849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436849.